Literature DB >> 8909809

The c-erbB3/HER3 receptor in human cancer.

W J Gullick1.   

Abstract

c-erbB3 is a receptor for NDF/heregulin that can engage in heterodimerization with other type I receptor tyrosine kinases. Despite very limited kinase activity, it can stimulate responses in heterodimers not evoked by other family members. It is overexpressed frequently in several common solid tumours and thus represents a target for new forms of therapies.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8909809

Source DB:  PubMed          Journal:  Cancer Surv        ISSN： 0261-2429


  24 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3.

Authors:  Xiao-Bo Qiu; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-31       Impact factor: 11.205

3.  Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Authors:  F J Esteva; G N Hortobagyi; A A Sahin; T L Smith; D M Chin; S Y Liang; L Pusztai; A U Buzdar; S S Bacus
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 4.  Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors.

Authors:  Jörgen Carlsson
Journal:  Tumour Biol       Date:  2012-01-07

5.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

6.  Induction of Smad1 by MT1-MMP contributes to tumor growth.

Authors:  Jaclyn A Freudenberg; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Authors:  A Craig Lockhart; Yongjian Liu; Farrokh Dehdashti; Richard Laforest; Joel Picus; Jennifer Frye; Lauren Trull; Stefanie Belanger; Madhuri Desai; Syed Mahmood; Jeanne Mendell; Michael J Welch; Barry A Siegel
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 9.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

Review 10.  Multimodality imaging of the HER-kinase axis in cancer.

Authors:  Weibo Cai; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.